Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Accelerate Diagnostics initiated with a Neutral at BTIG » 16:49
10/07/20
10/07
16:49
10/07/20
16:49
AXDX

Accelerate Diagnostics

$11.19 /

+0.34 (+3.13%)

BTIG analyst Mark Massaro…

BTIG analyst Mark Massaro initiated coverage of Accelerate Diagnostics with a Neutral rating. The analyst is positive on the company's new leadership, discipline, and products, but cited the early phase of new product launches, slight strategic pivot, and rich valuation for his Neutral rating.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$11.19 /

+0.34 (+3.13%)

AXDX Accelerate Diagnostics
$11.19 /

+0.34 (+3.13%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
AXDX Accelerate Diagnostics
$11.19 /

+0.34 (+3.13%)

AXDX Accelerate Diagnostics
$11.19 /

+0.34 (+3.13%)

AXDX Accelerate Diagnostics
$11.19 /

+0.34 (+3.13%)

Conference/Events
Accelerate Diagnostics participates in a conference call hosted by Craig Hallum » 04:55
09/24/20
09/24
04:55
09/24/20
04:55
AXDX

Accelerate Diagnostics

$10.66 /

-0.49 (-4.39%)

Conference call with…

Conference call with management will be held on September 24 hosted by Craig Hallum.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$10.66 /

-0.49 (-4.39%)

AXDX Accelerate Diagnostics
$10.66 /

-0.49 (-4.39%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
AXDX Accelerate Diagnostics
$10.66 /

-0.49 (-4.39%)

AXDX Accelerate Diagnostics
$10.66 /

-0.49 (-4.39%)

AXDX Accelerate Diagnostics
$10.66 /

-0.49 (-4.39%)

Conference/Events
Accelerate Diagnostics participates in a conference call hosted by Craig Hallum » 11:42
09/23/20
09/23
11:42
09/23/20
11:42
AXDX

Accelerate Diagnostics

$11.33 /

+0.18 (+1.61%)

Conference call with…

Conference call with management will be held on September 24 hosted by Craig Hallum.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$11.33 /

+0.18 (+1.61%)

AXDX Accelerate Diagnostics
$11.33 /

+0.18 (+1.61%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
AXDX Accelerate Diagnostics
$11.33 /

+0.18 (+1.61%)

AXDX Accelerate Diagnostics
$11.33 /

+0.18 (+1.61%)

AXDX Accelerate Diagnostics
$11.33 /

+0.18 (+1.61%)

Over a month ago
Hot Stocks
Accelerate Diagnostics announces FDA clearance for Accelerate Pheno improvements » 09:03
09/16/20
09/16
09:03
09/16/20
09:03
AXDX

Accelerate Diagnostics

$10.76 /

-0.24 (-2.18%)

Accelerate Diagnostics…

Accelerate Diagnostics announced that the company has received U.S. FDA clearance for a new suite of product enhancements to the Accelerate Pheno system, which improve performance and expand the system's antimicrobial susceptibility testing menu for bloodstream infections. The new product release, formally classified as FDA 510(k) Clearance No. K192665, features improvements in susceptibility testing performance for four important antibiotics used to treat Pseudomonas aeruginosa, as well as the addition of the combination of P. aeruginosa and aztreonam, an empiric antibiotic, to the Accelerate PhenoTest BC kit testing panel.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$10.76 /

-0.24 (-2.18%)

AXDX Accelerate Diagnostics
$10.76 /

-0.24 (-2.18%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
AXDX Accelerate Diagnostics
$10.76 /

-0.24 (-2.18%)

AXDX Accelerate Diagnostics
$10.76 /

-0.24 (-2.18%)

AXDX Accelerate Diagnostics
$10.76 /

-0.24 (-2.18%)

Hot Stocks
Accelerate Diagnostics: FDA issues EUA for individual IgM, IgG antibody tests » 09:02
09/10/20
09/10
09:02
09/10/20
09:02
AXDX

Accelerate Diagnostics

$9.97 /

-0.42 (-4.04%)

Accelerate Diagnostics…

Accelerate Diagnostics announced that the U.S. FDA has issued an Emergency Use Authorization for the individual BioCheck SARS-CoV-2 IgM Test Kit and the BioCheck SARS-CoV-2 IgG Test Kit. This announcement follows the recent EUA approval of the fully automated MS-Fast instrument and the BioCheck SARS-CoV-2 IgM and IgG Combo Test. In accordance with the previously disclosed commercial supply and collaboration agreement, Accelerate Diagnostics will market, commercialize, and support this serology-based testing platform. The MS-Fast system and BioCheck SARS-CoV-2 chemiluminescence tests are capable of processing human serum samples in 30 minutes to detect antibodies that indicate recent or prior COVID-19 infection.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$9.97 /

-0.42 (-4.04%)

AXDX Accelerate Diagnostics
$9.97 /

-0.42 (-4.04%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
AXDX Accelerate Diagnostics
$9.97 /

-0.42 (-4.04%)

AXDX Accelerate Diagnostics
$9.97 /

-0.42 (-4.04%)

AXDX Accelerate Diagnostics
$9.97 /

-0.42 (-4.04%)

Hot Stocks
Accelerate Diagnostics names Nedal Safwat Chief Strategy Officer » 09:16
08/24/20
08/24
09:16
08/24/20
09:16
AXDX

Accelerate Diagnostics

$13.53 /

-0.91 (-6.30%)

Accelerate Diagnostics…

Accelerate Diagnostics announced that Nedal Safwat has been appointed Chief Strategy Officer. Dr. Safwat joins Accelerate from BioMerieux, a microbiology diagnostics company.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$13.53 /

-0.91 (-6.30%)

AXDX Accelerate Diagnostics
$13.53 /

-0.91 (-6.30%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
AXDX Accelerate Diagnostics
$13.53 /

-0.91 (-6.30%)

AXDX Accelerate Diagnostics
$13.53 /

-0.91 (-6.30%)

AXDX Accelerate Diagnostics
$13.53 /

-0.91 (-6.30%)

On The Fly
Fly Intel: After-Hours Movers » 18:46
08/18/20
08/18
18:46
08/18/20
18:46
SUPN

Supernus

$25.04 /

+0.16 (+0.64%)

, AXDX

Accelerate Diagnostics

$14.86 /

+0.36 (+2.48%)

, ATGE

Adtalem Global Education

$35.96 /

+0.52 (+1.47%)

, JKHY

Jack Henry

$197.74 /

-1.38 (-0.69%)

, A

Agilent

$97.86 /

+0.34 (+0.35%)

, CREE

Cree

$68.50 /

-3.82 (-5.28%)

, EYEN

Eyenovia

$4.46 /

-0.04 (-0.89%)

, SRNE

Sorrento Therapeutics

$12.27 /

+0.18 (+1.49%)

, SABR

Sabre

$7.90 /

-0.16 (-1.99%)

, GNCA

Genocea

$2.73 /

-0.08 (-2.85%)

Check out this evening's…

ShowHide Related Items >><<
SUPN Supernus
$25.04 /

+0.16 (+0.64%)

SRNE Sorrento Therapeutics
$12.27 /

+0.18 (+1.49%)

SABR Sabre
$7.90 /

-0.16 (-1.99%)

JKHY Jack Henry
$197.74 /

-1.38 (-0.69%)

GNCA Genocea
$2.73 /

-0.08 (-2.85%)

EYEN Eyenovia
$4.46 /

-0.04 (-0.89%)

CREE Cree
$68.50 /

-3.82 (-5.28%)

AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

A Agilent
$97.86 /

+0.34 (+0.35%)

SUPN Supernus
$25.04 /

+0.16 (+0.64%)

06/16/20 Piper Sandler
Supernus upgraded to Overweight from Neutral at Piper Sandler
06/15/20 Jefferies
Supernus resumed with a Hold at Jefferies
04/30/20 Piper Sandler
Supernus price target raised to $25 from $17 at Piper Sandler
11/08/19 Berenberg
Supernus downgraded to Hold from Buy at Berenberg
AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
ATGE Adtalem Global Education
$35.96 /

+0.52 (+1.47%)

01/07/20 Barrington
Adtalem, Tivity, Virtusa among Barrington's Best Ideas for 2020
10/30/19 Barrington
Adtalem Global weakness a buying opportunity, says Barrington
09/12/19 Sidoti
Adtalem Global Education initiated with a Buy at Sidoti
08/23/19 BMO Capital
Adtalem Global Education price target raised to $55 from $50 at BMO Capital
JKHY Jack Henry
$197.74 /

-1.38 (-0.69%)

04/08/20 Wells Fargo
Jack Henry downgraded to Equal Weight from Overweight at Wells Fargo
03/11/20 Raymond James
Jack Henry's fundamentals outweigh healthy valuation, says Raymond James
03/11/20 Raymond James
Jack Henry upgraded to Outperform from Market Perform at Raymond James
02/06/20 DA Davidson
Jack Henry price target raised to $142 from $128 at DA Davidson
A Agilent
$97.86 /

+0.34 (+0.35%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
CREE Cree
$68.50 /

-3.82 (-5.28%)

08/17/20 Deutsche Bank
Cree price target raised to $60 from $45 at Deutsche Bank
08/12/20
Fly Intel: Top five analyst initiations
08/12/20 Citi
Cree initiated with a Neutral at Citi
06/09/20 Goldman Sachs
Cree downgraded to Neutral from Buy at Goldman Sachs
EYEN Eyenovia
$4.46 /

-0.04 (-0.89%)

03/26/20 H.C. Wainwright
Eyenovia price target lowered to $6 from $10 at H.C. Wainwright
02/03/20 Oppenheimer
Eyenovia downgraded to Perform from Outperform at Oppenheimer
10/30/19 H.C. Wainwright
Eyenovia price target lowered to $10 from $12 at H.C. Wainwright
SRNE Sorrento Therapeutics
$12.27 /

+0.18 (+1.49%)

07/31/20 H.C. Wainwright
Sorrento Therapeutics price target raised to $30 from $24 at H.C. Wainwright
07/20/20 Dawson James
Sorrento antibody cocktail effort could move quickly, says Dawson James
05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
10/07/19 JMP Securities
Sorrento Therapeutics initiated with an Outperform at JMP Securities
SABR Sabre
$7.90 /

-0.16 (-1.99%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
GNCA Genocea
$2.73 /

-0.08 (-2.85%)

07/30/20 Stifel
Genocea '009 efficacy boding well for more substantial update ahead, says Stifel
07/27/20 Stifel
Stifel recommends Genocea shares ahead of first look at GEN-009 efficacy
07/23/20 H.C. Wainwright
Genocea price target lowered to $9 from $32 at H.C. Wainwright
11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
SUPN Supernus
$25.04 /

+0.16 (+0.64%)

SABR Sabre
$7.90 /

-0.16 (-1.99%)

JKHY Jack Henry
$197.74 /

-1.38 (-0.69%)

GNCA Genocea
$2.73 /

-0.08 (-2.85%)

EYEN Eyenovia
$4.46 /

-0.04 (-0.89%)

CREE Cree
$68.50 /

-3.82 (-5.28%)

AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

ATGE Adtalem Global Education
$35.96 /

+0.52 (+1.47%)

A Agilent
$97.86 /

+0.34 (+0.35%)

  • 20
    Aug
  • 19
    Aug
SRNE Sorrento Therapeutics
$12.27 /

+0.18 (+1.49%)

CREE Cree
$68.50 /

-3.82 (-5.28%)

SRNE Sorrento Therapeutics
$12.27 /

+0.18 (+1.49%)

SABR Sabre
$7.90 /

-0.16 (-1.99%)

AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

A Agilent
$97.86 /

+0.34 (+0.35%)

SRNE Sorrento Therapeutics
$12.27 /

+0.18 (+1.49%)

SABR Sabre
$7.90 /

-0.16 (-1.99%)

CREE Cree
$68.50 /

-3.82 (-5.28%)

AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

ATGE Adtalem Global Education
$35.96 /

+0.52 (+1.47%)

A Agilent
$97.86 /

+0.34 (+0.35%)

Hot Stocks
Accelerate Diagnostics announces FDA EUA for COVID-19 antibody testing system » 16:16
08/18/20
08/18
16:16
08/18/20
16:16
AXDX

Accelerate Diagnostics

$14.86 /

+0.36 (+2.48%)

Accelerate Diagnostics…

Accelerate Diagnostics and BioCheck, a privately-held San Francisco-based company focused on in vitro diagnostics, announced that the FDA has issued an Emergency Use Authorization,. or EUA, for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument. In accordance with the previously disclosed commercial supply and collaboration agreement, Accelerate Diagnostics will market, commercialize, and support this serology-based testing platform. The MS-Fast system and BioCheck SARS-CoV-2 chemiluminescence tests are capable of processing human serum samples in 30 minutes to detect antibodies that indicate recent or prior COVID-19 infection.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

08/07/20 Craig-Hallum
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum
05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

AXDX Accelerate Diagnostics
$14.86 /

+0.36 (+2.48%)

Upgrade
Accelerate Diagnostics upgraded to Buy from Hold at Craig-Hallum » 06:35
08/07/20
08/07
06:35
08/07/20
06:35
AXDX

Accelerate Diagnostics

$14.72 /

-0.83 (-5.34%)

Craig-Hallum analyst Alex…

Craig-Hallum analyst Alex Novak upgraded Accelerate Diagnostics to Buy from Hold with a $20 price target.

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
09/27/19 JPMorgan
Accelerate Diagnostics downgraded to Underweight from Neutral at JPMorgan
AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

Earnings
Accelerate Diagnostics reports Q2 EPS (35c), consensus (34c) » 17:04
08/06/20
08/06
17:04
08/06/20
17:04
AXDX

Accelerate Diagnostics

$14.72 /

-0.83 (-5.34%)

Reports Q2 revenue $2.1M,…

Reports Q2 revenue $2.1M, consensus $2.46M. "While the progress of new contracts and go-lives continued to be slowed by the effects of the pandemic, utilization within our existing base of live Pheno instruments continued to prove durable during the second quarter," commented CEO Jack Phillips. "Despite these external disruptions, our internal R&D teams have made considerable progress, enabling today's announcement of several new products as part of our enhanced portfolio strategy. These include the immediate launch of an AST-only test kit and the imminent launch of a new workflow instrument, the PhenoPrep, the first application of which is enabling automated rapid MALDI identification results. We also entered into an exclusive supply and collaboration arrangement with Ascend Diagnostics to commercialize a complementary desktop MALDI instrument. We are excited about these new additions to our product portfolio and believe they will help position Accelerate for sustained success and more rapid adoption of our technology as the market continues to recover from the unprecedented impacts of COVID-19."

ShowHide Related Items >><<
AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

05/11/20 Piper Sandler
Accelerate Diagnostics price target lowered to $14 from $16 at Piper Sandler
01/14/20 Piper Sandler
Accelerate Diagnostics price target raised to $20 from $16 at Piper Sandler
09/27/19 JPMorgan
JPMorgan downgrades Accelerate Diagnostics to Underweight on estimate risk
09/27/19 JPMorgan
Accelerate Diagnostics downgraded to Underweight from Neutral at JPMorgan
AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

AXDX Accelerate Diagnostics
$14.72 /

-0.83 (-5.34%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.